Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6NSCLC 5Respiratory Tract Neoplasms 1Lung Neoplasms 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1Bronchial Neoplasms 1Advanced Non-small Cell Lung Cancer 1Advanced NSCLC Patients With T790M 1Advanced NSCLC 1Advanced Lung Cancer 1

Interventions

famitinib 1camrelizumab 1aflutinib 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced NSCLC × aflutinib × Clear all
NCT03127449 2025-04-03

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Allist Pharmaceuticals, Inc.

Phase NA Terminated
116 enrolled
Thoracic

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡